RB1 and neoplasm: The lack of RB1 sequencing at baseline and the challenge of obtaining tumor biopsy for genomic screening purposes in the context of advanced sarcoma patients, additionally hindered by the SARS-CoV2 pandemic, have been limitations of the trial.